Skip to main content
SpringerLink
Log in

A Comparative Study Between Tumor Blood Vessels and Dynamic Contrast-enhanced MRI for Identifying Isocitrate Dehydrogenase Gene 1 (IDH1) Mutation Status in Glioma

  • Published:
Current Medical Science Aims and scope Submit manuscript

Abstract

Objective

Isocitrate dehydrogenase gene (IDH) mutations are associated with tumor angiogenesis and therefore play an important role in glioma management. This study compared the performance of tumor blood vessels counted from contrast-enhanced 3D brain volume (3D-BRAVO) sequence and dynamic contrast-enhanced (DCE) MRI in differentiating IDH1 status in gliomas.

Methods

Forty-four glioma patients [16 with IDH1 mutant-type (IDH1-MT), 28 with IDH1 wild-type (IDH1-WT)] were retrospectively analyzed. A blood vessel entering a tumor was defined as an intratumoral vessel; a blood vessel adjacent to the edge of a tumor was defined as a peritumoral vessel. Combined vessels were defined as the sum of the intratumoral and peritumoral vessels. DCE-derived metrics of tumor were normalized to the contralateral normal-appearing white matter.

Results

Intratumoral, peritumoral, and combined tumor blood vessels were all significantly different between IDH1-MT and IDH1-WT gliomas, and the range of area under curves (AUCs) was 0.816–0.855. For DCE-derived parameters, cerebral blood volume, cerebral blood flow, mean transit time, and volume transfer constant were significantly different between IDH1-MT and IDH1-WT gliomas, and the range of AUCs was 0.703–0.756. Combined vessels possessed the best performance for identifying IDH1 mutations in gliomas (AUC: 0.855, sensitivity: 0.857, specificity: 0.812, P<0.001).

Conclusion

The number of tumor blood vessels has comparable diagnostic performance with DCE-derived parameters for differentiating IDH1 mutations and can serve as a potential imaging biomarker to reflect IDH1 mutations in gliomas.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bello L, Giussani C, Carrabba G, et al. Angiogenesis and invasion in gliomas. Cancer Treat Res, 2004,117:263–284

    Article  CAS  Google Scholar 

  2. Burger PC, Vogel FS, Green SB, et al. Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications. Cancer, 1985,56 (5):1106–1111

    Article  CAS  Google Scholar 

  3. Daumas-Duport C, Tucker ML, Kolles H, et al. Oligodendrogliomas. Part II: A new grading system based on morphological and imaging criteria. J Neurooncol, 1997,34(1):61–78

    Article  CAS  Google Scholar 

  4. Abdulrauf SI, Edvardsen K, Ho KL, et al. Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma. J Neurosurg, 1998,88(3):513–520

    Article  CAS  Google Scholar 

  5. Hardee ME, Zagzag D. Mechanisms of glioma-associated neovascularization. Am J Pathol, 2012,181 (4):1126–1141

    Article  CAS  Google Scholar 

  6. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathologica, 2016,131(6):803–820

    Article  Google Scholar 

  7. Lai A, Kharbanda S, Pope WB, et al. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol, 2011,29(34):4482–4490

    Article  CAS  Google Scholar 

  8. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med, 2009,360(8):765–773

    Article  CAS  Google Scholar 

  9. Balss J, Meyer J, Mueller W, et al. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol, 2008,116(6):597–602

    Article  CAS  Google Scholar 

  10. Dang L, White D W, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature, 2009,462(7274):739–744

    Article  CAS  Google Scholar 

  11. Ye D, Ma S, Xiong Y, et al. R-2-hydroxyglutarate as the key effector of IDH mutations promoting oncogenesis. Cancer Cell, 2013,23(3):274–276

    Article  CAS  Google Scholar 

  12. Koivunen P, Lee S, Duncan CG, et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature, 2012,483(7390):484–488

    Article  CAS  Google Scholar 

  13. Kickingereder P, Sahm F, Radbruch A, et al. IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma. Sci Rep, 2015,5:16238

    Article  CAS  Google Scholar 

  14. Turkalp Z, Karamchandani J, Das S. IDH mutation in glioma: new insights and promises for the future. JAMA Neurol, 2014,71(10):1319–1325

    Article  Google Scholar 

  15. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol, 2009,27(28):4733–4740

    Article  CAS  Google Scholar 

  16. Tovi M, Lilja A, Bergstrom M, et al. Delineation of gliomas with magnetic resonance imaging using Gd-DTPA in comparison with computed tomography and positron emission tomography. Acta Radiol, 1990,31(5):417–429

    Article  CAS  Google Scholar 

  17. Jahng GH, Li KL, Ostergaard L, et al. Perfusion magnetic resonance imaging: a comprehensive update on principles and techniques. Korean J Radiol, 2014, 15(5):554–577

    Article  Google Scholar 

  18. Brendle C, Hempel JM, Schittenhelm J, et al. Glioma Grading and Determination of IDH Mutation Status and ATRX loss by DCE and ASL Perfusion. Clin Neuroradiol, 2018,28(3):421–428

    Article  Google Scholar 

  19. You SH, Choi SH, Kim TM, et al. Differentiation of High-Grade from Low-Grade Astrocytoma: Improvement in Diagnostic Accuracy and Reliability of Pharmacokinetic Parameters from DCE MR Imaging by Using Arterial Input Functions Obtained from DSC MR Imaging. Radiology, 2018,286(3):981–991

    Article  Google Scholar 

  20. Patel SH, Poisson LM, Brat DJ, et al. T2—FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project. Clin Cancer Res, 2017,23(20):6078–6085

    Article  CAS  Google Scholar 

  21. Xi Y, Kang X, Wang N, et al. Differentiation of primary central nervous system lymphoma from high-grade glioma and brain metastasis using arterial spin labeling and dynamic contrast-enhanced magnetic resonance imaging. Eur J Radiol, 2019,112:59–64

    Article  Google Scholar 

  22. Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging, 1997,7(1):91–101

    Article  CAS  Google Scholar 

  23. Kellner E, Breyer T, Gall P, et al. MR evaluation of vessel size imaging of human gliomas: Validation by histopathology. J Magn Reson Imaging, 2015,42(4): 1117–1125

    Article  Google Scholar 

  24. Lemasson B, Valable S, Farion R, et al. In vivo imaging of vessel diameter, size, and density: a comparative study between MRI and histology. Magn Reson Med, 2013,69(1):18–26

    Article  Google Scholar 

  25. Kiselev V G, Strecker R, Ziyeh S, et al. Vessel size imaging in humans. Magn Reson Med, 2005,53(3):553–563

    Article  CAS  Google Scholar 

  26. Tropres I, Grimault S, Vaeth A, et al. Vessel size imaging. Magn Reson Med, 2001,45(3):397–408

    Article  CAS  Google Scholar 

  27. Guo H, Kang H, Tong H, et al. Microvascular characteristics of lower-grade diffuse gliomas: investigating vessel size imaging for differentiating grades and subtypes. Eur Radiol, 2019,29(4):1893–1902

    Article  Google Scholar 

  28. Stadlbauer A, Zimmermann M, Kitzwogerer M, et al. MR Imaging-derived Oxygen Metabolism and Neovascularization Characterization for Grading and IDH Gene Mutation Detection of Gliomas. Radiology, 2017,283(3):799–809

    Article  Google Scholar 

  29. Kleihues P, Soylemezoglu F, Schauble B, et al. Histopathology, classification, and grading of gliomas. Glia, 1995,15(3):211–221

    Article  CAS  Google Scholar 

  30. Jafari-Khouzani K, Loebel F, Bogner W, et al. Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients. Neuro Oncol, 2016,18(11):1569–1578

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Mur P, Mollejo M, Hernández-Iglesias T, et al. Molecular Classification Defines 4 Prognostically Distinct Glioma Groups Irrespective of Diagnosis and Grade. J Neuropathol Exp Neurol, 2015,74(3):241–249

    Article  CAS  Google Scholar 

  32. Beiko J, Suki D, Hess K R, et al. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol, 2014,16(1):81–91

    Article  CAS  Google Scholar 

  33. Pellegatta S, Valletta L, Corbetta C, et al. Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma. Acta Neuropathol Commun, 2015,3:4

    Article  Google Scholar 

  34. Rohle D, Popovici-Muller J, Palaskas N, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science, 2013,340(6132):626–630

    Article  CAS  Google Scholar 

  35. Turcan S, Fabius AW, Borodovsky A, et al. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. Oncotarget, 2013,4(10):1729–1736

    Article  Google Scholar 

  36. Gomez-Manzano C, Holash J, Fueyo J, et al. VEGF Trap induces antiglioma effect at different stages of disease. Neuro Oncol, 2008,10(6):940–945

    Article  Google Scholar 

  37. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A, 2002,99(17):11393–11398

    Article  CAS  Google Scholar 

  38. Cortes-Santiago N, Hossain MB, Gabrusiewicz K, et al. Soluble Tie2 overrides the heightened invasion induced by anti-angiogenesis therapies in gliomas. Oncotarget, 2016,7(13):16146–16157

    Article  Google Scholar 

  39. Huang H, Bhat A, Woodnutt G, et al. Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer, 2010,10(8):575–585

    Article  CAS  Google Scholar 

  40. Chae SS, Kamoun WS, Farrar CT, et al. Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas. Clin Cancer Res, 2010,16(14):3618–3627

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China

    Shi-hui Li, Nan-xi Shen, Di Wu, Ju Zhang, Jia-xuan Zhang, Jing-jing Jiang & Wen-zhen Zhu

Authors
  1. Shi-hui Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nan-xi Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Di Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ju Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jia-xuan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jing-jing Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Wen-zhen Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wen-zhen Zhu.

Additional information

Conflict of Interest Statement

The authors declare that they have no conflicts of interest.

Author Wen-zhen ZHU is a member of the Editorial Board for [Current Medical Science]. The paper was handled by other editors and has undergone rigorous peer review process. Author Wen-zhen ZHU was not involved in the journal’s review of, or decisions related to, this manuscript.

This study was supported by the National Natural Science Foundation of China (No. 81730049 and No. 81801666) and the Fundamental Research Funds for the Central Universities, HUST (No. 2019JYCXJJ044).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, Sh., Shen, Nx., Wu, D. et al. A Comparative Study Between Tumor Blood Vessels and Dynamic Contrast-enhanced MRI for Identifying Isocitrate Dehydrogenase Gene 1 (IDH1) Mutation Status in Glioma. CURR MED SCI 42, 650–657 (2022). https://doi.org/10.1007/s11596-022-2563-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11596-022-2563-y

Key words

Search

Navigation